Evidence map›Paper›PMID 36163163›Full record

ArticleJournal of geriatric oncology2023

'ADVANCE' (a pilot trial) ADjuVANt chemotherapy in the elderly: Developing and evaluating lower-toxicity chemotherapy options for older patients with breast cancer.

Rachel A Freedman, Tianyu Li, Mina S Sedrak, Judith O Hopkins, Nabihah Tayob, Meredith G Faggen, Natalie F Sinclair, Wendy Y Chen, Heather A Parsons, Erica L Mayer and 11 more

Registry-linked trialOpen access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of geriatric oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03858322 ('ADVANCE'), which is not on this map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03858322 phase1active not recruitingnot on this map

'ADVANCE' (A Pilot Trial) ADjuVANt Chemotherapy in the Elderly: Developing and Evaluating Lower-Toxicity Chemotherapy Options for Older Patients With Breast Cancer

TypeinterventionalSponsorDana-Farber Cancer InstituteRan2019 to 2026Enrolled41ConditionsBreast CancerArmsPaclitaxel, Cyclophosphamide, Carboplatin
3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Ageing, immune fitness and cancer.Nature reviews. Cancer · 2025
    Review
  5. Clonal Hematopoiesis in Women With Breast Cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025
    Review
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 4 institutions in 1 country.

Rachel A FreedmanMedical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA; Harvard Medical School, Boston, MA, USA. Electronic address: rafreedman@partners.org.
Tianyu LiDepartment of Data Sciences, Dana-Farber Cancer Institute, Boston, MA, USA.
Mina S SedrakDepartment of Medical Oncology and Therapeutics Research, City of Hope, Duarte, CA, USA.
Judith O HopkinsNovant Health Cancer Institute / SCOR NCORP, Winston Salem, NC, USA.
Nabihah TayobHarvard Medical School, Boston, MA, USA; Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA, USA.
Meredith G FaggenDana-Farber Brigham Cancer Center at South Shore Hospital, South Weymouth, MA, USA.
Natalie F SinclairDana-Farber Brigham Cancer Center at Milford Regional Medical Center, Milford, MA, USA.
Wendy Y ChenMedical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA; Harvard Medical School, Boston, MA, USA.
Heather A ParsonsMedical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA; Harvard Medical School, Boston, MA, USA.
Erica L MayerMedical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA; Harvard Medical School, Boston, MA, USA.
Paulina B LangeMedical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Ameer S BastaMedical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Adriana Perilla-GlenMedical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Ruth I LedermanMedical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Andrew WongDepartment of Medical Oncology and Therapeutics Research, City of Hope, Duarte, CA, USA.
Abhay TiwariDepartment of Medical Oncology and Therapeutics Research, City of Hope, Duarte, CA, USA.
Sandra S McAllisterHarvard Medical School, Boston, MA, USA; Hematology Division, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA; Harvard Stem Cell Institute, Cambridge, MA, USA; Broad Institute of the Massachusetts Institute of Technology and Harvard University, Cambridge, MA, USA.
Elizabeth A MittendorfBreast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, Boston, MA, USA.
Peter G MillerHarvard Medical School, Boston, MA, USA; Broad Institute of the Massachusetts Institute of Technology and Harvard University, Cambridge, MA, USA; Center for Cancer Research, Massachusetts General Hospital, Boston, MA, USA.
Christopher J GibsonMedical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA.
Harold J BursteinMedical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA; Harvard Medical School, Boston, MA, USA.
Dana-Farber Cancer Institute · USCity of Hope · USDana-Farber Brigham Cancer Center · USSouth Shore Hospital · US

Funding

Oncology Research Career Development ProgramK12CA001727 · NCI · CITY OF HOPE NATIONAL MEDICAL CENTER · PI MORTIMER, JOANNE E. · 1992 to 2024
$14.6M
Role of PPM1D and PPM1D mutations in hematopoiesis and response to stressK08CA263183 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI MILLER, PETER GRANT · 2021 to 2025
$1.1M
Targeting Senescence to Improve Frailty in Older Cancer SurvivorsK76AG074918 · NIA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI SEDRAK, MINA S · 2022 to 2024
$729k
Improving Clinical Trial Participation of Older Adults with CancerR03AG064377 · NIA · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI SEDRAK, MINA S · 2019 to 2020
$260k
NCI NIH HHS K08 CA263183NCI NIH HHS K12 CA001727NIA NIH HHS K76 AG074918NIA NIH HHS R03 AG064377
6 · The paper itself

Abstract

introductionOlder adults with breast cancer receiving neo/adjuvant chemotherapy are at high risk for poor outcomes and are underrepresented in clinical trials. The ADVANCE (ADjuVANt Chemotherapy in the Elderly) trial evaluated the feasibility of two neo/adjuvant chemotherapy regimens in parallel-enrolling cohorts of older patients with human epidermal growth factor receptor 2-negative breast cancer: cohort 1-triple-negative; cohort 2-hormone receptor-positive. MATERIALS AND

methodsAdults age ≥ 70 years with stage I-III breast cancer warranting neo/adjuvant chemotherapy were enrolled. Cohort 1 received weekly carboplatin (area under the curve 2) and weekly paclitaxel 80 mg/m

resultsForty women (n = 20 per cohort) were enrolled from March 25, 2019 through August 3, 2020 from three centers; 45% and 35% of patients in cohorts 1 and 2 were age > 75, respectively. Neither cohort achieved targeted thresholds for feasibility. In cohort 1, eight (40.0%) met feasibility (95% confidence interval [CI] = 19.1-63.9%), while ten (50.0%) met feasibility in cohort 2 (95% CI = 27.2-72.8). Neutropenia was the most common grade 3-4 toxicity (cohort 1-65%, cohort 2-55%). In cohort 1, 80% and 85% required ≥1 dose holds of carboplatin and/or paclitaxel, respectively. In cohort 2, 10% required dose hold(s) for cyclophosphamide and/or 65% for paclitaxel. DISCUSSION: In this pragmatic pilot examining chemotherapy regimens in older adults with breast cancer, neither regimen met target goals for feasibility. Developing efficacious and tolerable regimens for older patients with breast cancer who need chemotherapy remains an important goal. CLINICALTRIALS: gov Identifier: NCT03858322.

Indexed as

Breast NeoplasmsAgedAntineoplastic Combined Chemotherapy ProtocolsCarboplatinChemotherapy, AdjuvantCyclophosphamideFemaleHumansPaclitaxelPilot ProjectsCarboplatinCyclophosphamidePaclitaxelBreast cancerCarboplatinChemotherapyCyclophosphamideOlder adultsPaclitaxel

Identifiers

PMID36163163
PMCPMC10080267
OpenAlexW4296889317

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.